Xilio Therapeutics/$XLO
1D1W1MYTD1Y5YMAX
Capital at risk
About Xilio Therapeutics
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
- Ticker
- $XLO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 76
- Headquarters
- Waltham, United States
- Website
- xiliotx.com
XLO Metrics
BasicAdvanced
$59M
-
-$3.32
-0.12
-
Price and volume
Market cap
$59M
Beta
-0.12
52-week high
$9.90
52-week low
$6.68
Average daily volume
13K
Financial strength
Current ratio
4.254
Quick ratio
4.153
Long term debt to equity
6.749
Total debt to equity
8.722
Profitability
EBITDA (TTM)
-30.03
Gross margin (TTM)
83.16%
Net profit margin (TTM)
-34.06%
Operating margin (TTM)
-48.94%
Revenue per employee (TTM)
$840,000
Management effectiveness
Return on assets (TTM)
-13.61%
Return on equity (TTM)
-55.03%
Valuation
Price to revenue (TTM)
0.915
Price to book
0.81
Price to tangible book (TTM)
0.81
Price to free cash flow (TTM)
-0.957
Free cash flow yield (TTM)
-104.50%
Free cash flow per share (TTM)
-9.311
Growth
Revenue change (TTM)
327.25%
Earnings per share change (TTM)
-78.16%
3-year earnings per share growth (CAGR)
-57.43%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.